The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 171-174

  Krijnen, José L M ^a   Bogdanowicz, Jacques F A T ^a   Seldenrijk, Cees A ^a   Mulder, Paul G H ^a   Van Der Kwast, Theodorus H ^a  

^a NONE

Author keywords

Adenocarcinoma; Endocrinology; Neuroendocrinology; Prostatic neoplasms

Indexed keywords

CHROMOGRANIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; DISEASE COURSE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; SURVIVAL RATE; TISSUE FIXATION; TRANSURETHRAL RESECTION;

EID: 0030947224     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00054     Document Type: Article

References (21)

1. Catalona, W. J.: Management of cancer of the prostate. New Engl. J. Med. 331: 996, 1994.
2. Partin, A. W., Steinberg, G. D., Pitcock, R. V., Wu, L., Piantadosi, S., Coffey D. S. and Epstein, J. I.: Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer, 70: 161, 1992.
3. Di Sant'Agnese, P. A. and Cockett, A. T. K.: The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J. Urol., 152: 1927, 1994.
4. Oesterling, J., Hauzeur, C. and Farrow, G.: Small cell anaplastic carcinoma of the prostate: a clinical pathologyal and immunohistological study of 27 patients. J. Urol., 147: 804, 1992.
5. Aprikian, A., Cordon-Cardo, C., Fair, W. and Reuter V.: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer, 71: 3952, 1993.
6. Abrahamsson P.-A., Wadstrom, L. B., Alumets, J., Falkmer, S. and Grimelius, L.: Peptide-hormone and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Path. Res. Pract., 182: 298, 1987.
7. Abrahamsson, P. A., Falkmer, S., Falt, K. and Grimelius, L.: The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an "endocrine marker." Path. Res. Pract 185: 373, 1989.
8. Cohen, R. J., Glezerson, G., Haffejee, Z. and Afrika D.: Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Brit. J. Urol., 66: 405, 1990.
9. Cohen, R. J., Glezerson, G. and Haffejee, Z.: Neuro-endocrine cells - a new prognostic parameter in prostate cancer. Brit. J. Urol., 68: 258, 1991.
10. Cohen, M. K., Arber, D. A., Coffield, K. S., Keegan, G. T., McClintock, J. and Speights, V. O., Jr.: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer, 74: 1899, 1994.
11. Noordzij, M. A., van der Kwast, T. H., van Steenbrugge, G. J., Hop, W. J. and Schroder, F. H.: The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int. J. Cancer, 62: 252, 1995.
12. Kadmon, D., Thompson, T., Lynch, G. and Scardino, P.: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J. Urol., 146: 358, 1991.
13. Tarle, M. and Rados, N.: Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate, 19: 23, 1991.
14. Bonkoff, H., Stein, U. and Remberger, K.: Androgen receptor status in endocrine-paracrine cell types of the normal, hyper-plastic, and neoplastic human prostate. Virch. Arch. Path., 423: 291, 1993.
15. Krijnen, J. L., Janssen, P. J., Ruizeveld de Winter, J. A., van Krimpen, H., Schroder, F. H. and van der Kwast, T. H.: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry, 100: 393, 1993.
16. Di Sant'Agnese, P. A. and de Mesy Jensen, K. L.: Neuroendocrine differentiation in prostatic carcinoma. Hum. Path., 18: 849, 1987.
17. Schröder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso M.: TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
18. Cox, D. R.: Regression models and life tables. J. Roy. Stat. Soc. B., 34: 187, 1972.
19. Bubendorf, L., Sauter, G., Moch, H., Schmid H. P., Gasser, T. C., Jordan, P. and Mihatsch, M. J.: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J. Path., 178: 437, 1996.
20. Bonkoff, H., Wernert, N., Dhom, G. and Remberger, K.: Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate, 19: 91, 1991.
21. Bang, Y. J., Pirnia, F., Fang, W. G., Kang, W. K., Sartor, O., Whitesell, L., Ha, M. J., Tsokos, M., Sheahan, M. D. Nguyen, P., Niklinski, W. T., Myers, C. E. and Trepel, J. B.: Terminal neuroendocrine differentiation of human prostate cardnoma cells in response to increased intracellular cyclic AMP. Proc. Natl. Acad. Sci., 91: 5330, 1994.